Seres Therapeutics, Inc. (MCRB)
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
Seres Therapeutics (MCRB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Conference Call Participants Tessa Romero - JPMorgan Chase & Co. Edward Tenthoff - Piper Sandler Peyton Bohnsack - TD Cowen Operator Good day, and thank you for standing by. At this time, I would like to welcome everyone to Seres Therapeutics Second Quarter 2024 Earnings Conference Call.
